

## **NHLBI Presentations ATS 2023**

*\*Sessions are held in the Walter E. Washington Convention Center unless otherwise noted.*

### ***Sunday, May 21***

L3: Recent Clinical and Omics Findings In Patients With Pulmonary Hypertension From The NHLBI PVDOMICS Program

Lei Xiao, M.D., Ph.D.

12-1 p.m. ET

Room 202 A (Level 2)

L5: Cutting Edge in Translation – NHLBI CATALYZE Program

Guofei Zhou, Ph.D.

12-1 p.m. ET

Room 204 A-C (Level 2)

L6: Community Results from Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities

Michelle Freemer, M.D., M.P.H.

12-1 p.m. ET

Room 145 A-B (Street Level)

### ***Monday, May 22***

Late-Breaking: B14: Dual Energy CT (DECT)-derived Ventilation/perfusion (V'/Q') Mismatch Following COVID-19 Infection: Preliminary Results from the Lung Microvascular and Parenchymal Sequelae (Lung-MaPS) of COVID-19 Study

Elizabeth Oelsner, M.D., M.P.H.

9:24-9:36 a.m. ET

Room 202 A (Level 2)

Late-Breaking: B14: Longitudinal Evaluation of Quantitative Computed Tomography Measurements and Diffusion Capacity of the Lung in Recovered COVID-19 Patients with Normal Chest Computed Tomography Scans

Simone Lee

9:36-9:48 a.m. ET

Room 202 A (Level 2)

Late-Breaking: B14: Association of Smoking History With COVID-19 Infection, Hospitalization and Death in the C4R Study

Pallavi Balte, M.B.B.S., M.P.H., Ph.D.

10-10:12 a.m. ET

Room 202 A (Level 2)

B7: Curative Therapies for Sickle Cell Disease: Potential Cures for SCD but What About the Lung?

Courtney Fitzhugh, M.D.

10:13-10:26 a.m. ET

Room 145 A-B (Street Level)

L12: The Molecular Atlas of Lung Development (LUNGMAP), Phase 2  
Sara Lin, Ph.D.  
12-1 p.m. ET  
Room 204 A-C (Level 2)

L14: Update on Preclinical Models of IPF – An NHLBI Consortium  
Matt Craig, Ph.D.  
12-1 p.m. ET  
Room 143 A-C (Street Level)

L8: Pursuing the Right Funding Source: Institutes, Organizations and Foundations Share Their Funding Priorities  
Siddharth Shenoy, Ph.D.  
12:13-12:21 p.m. ET  
Room 102 A-B (Street Level)

B92: Innovative Approaches to Personalized Severe Asthma Management  
Hannah Durrington, Ph.D., M.A., MBChB  
2:15-3:45 p.m. ET  
Ballroom B (Level 3)

***Tuesday, May 23, 2023***

C10: Sleep Deficiency as a Core Feature of OUD and Recovery: A Research Agenda  
Aaron Laposky, Ph.D.  
9-10:30 a.m. ET  
Room 145 A-B (Street Level)

L16: Impact of Sex and Gender on Autoimmune Lung Disease  
Louis Vuga, M.D., M.P.H., Ph.D.  
12-1 p.m. ET  
Room 152 A-B (Street Level)

L19: NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Network  
James Kiley, Ph.D.  
12-1 p.m. ET  
Room 204 A-C (Level 2)

L21: New Findings from the Subpopulations and Intermediate Outcome Measures in COPD II (SPIROMICS II) Study  
Lisa Postrow, Ph.D.  
12-1 p.m. ET  
Room 143 A-C (Street Level)

C88: Biological Impact of COVID-19 Across the Lifespan  
Lael Yonker, M.D.  
2:15-3:45 p.m. ET  
Marriott Marquis Washington, Marquis Ballroom, Salon 5 (Level M2)

***Wednesday, May 24, 2023***

D21: Longitudinal Evaluation of Blood Cellular Immune Markers and Lung Proteomics in Vaccinated Patients with SARS-CoV-2 Breakthrough Infections

Julio Huapaya, M.D., M.H.S.

8-10 a.m. ET

Room 206 (Level 2)

D19: Perivascular Neuronal  $\beta$ -III Tubulin (Tuj1) Diminishes the Severity of Pulmonary Fibrosis

Ryo Sato, M.D., Ph.D.

8:36-8:48 a.m. ET

Room 146 A-C (Street Level)

D16: Plasma SARS-CoV-2 Nucleocapsid Antigen Levels Are Associated with In-hospital Mortality in Hospitalized Patients With COVID-19

Kathryn Sullivan, M.D.

9:12-9:24 a.m. ET

Ballroom B (Level 3)

L22: The NHLBI Lung Transplant Consortium

Matt Craig, Ph.D.

10:30-11:30 a.m. ET

Room 202 B (Level 2)

L25: ELAFIN: From Translational PPG to Clinical Trial

Lei Xiao, Ph.D.

10:30-11:30 a.m. ET

Room 147 A-B (Street Level)

D93: Association Between Hospital Surge Strain and Mortality During the COVID-19 Pandemic: Global Patterns from a Scoping Review

Maniraj Neupane, M.D., Ph.D.

12-12:12 p.m. ET

Ballroom C (Level 3)